Rigel Pharmaceuticals (RIGL) stock price is $48.11, up 2.98% on the day, as of Oct 20, 2026. It has a market cap of $889.04Mn and a P/E ratio of 2.76, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap889.04 Mn
P/E2.76
P/S3.21
Div. Yield0.00
Total Debt (Qtr)78.47 Mn
Revenue Growth (1y) (Qtr)-22.60
Add ratio to table…
About
Rigel Pharmaceuticals Inc is a biotechnology company focused on developing and delivering novel therapies for patients with hematologic disorders and cancer. The company concentrates on targeting signaling pathways that are central to disease mechanisms. Its approved product portfolio includes TAVALISSE for chronic immune thrombocytopenia REZLIDHIA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation and GAVRETO for metastatic RET fusion…
Rigel Pharmaceuticals Inc is a biotechnology company focused on developing and delivering novel therapies for patients with hematologic disorders and cancer. The company concentrates on targeting signaling pathways that are central to disease mechanisms. Its approved product portfolio includes TAVALISSE for chronic immune thrombocytopenia REZLIDHIA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation and GAVRETO for metastatic RET fusion positive non small cell lung cancer and certain thyroid cancers. Rigel also advances a pipeline of investigational candidates such as the dual interleukin receptor associated kinase 1 and 4 inhibitor R289 for lower risk myelodysplastic syndrome and continues to explore additional indications for its existing assets through internal research and collaborations with academic institutions and other pharmaceutical firms.
Rigel generates revenue primarily from the sale of its approved products TAVALISSE REZLIDHIA and GAVRETO to patients through prescription channels. In 2025 net product sales were $158.8 million for TAVALISSE $31.0 million for REZLIDHIA and $42.1 million for GAVRETO. In addition to product sales the company earns income from collaboration and licensing agreements. For example Rigel recognized contract revenue from its partnership with Lilly after opting out of further cost sharing for the osteoclast inhibitor program. The company also receives milestone payments and royalties from partners such as Kissei and Dr. Reddy’s for the commercialization of its products in territories outside the United States. These streams complement product sales and contribute to overall financial performance.
Rigel operates in a highly competitive biotechnology and pharmaceutical landscape where it faces established therapies and emerging rivals. For TAVALISSE the main competitors include corticosteroid treatments thrombopoietin receptor agonists such as romiplostim and eltrombopag and the newly approved drug wayrilz. The company’s advantage lies in its distinct mechanism of action as a spleen tyrosine kinase inhibitor which offers an alternative for patients who have failed standard therapies. In the relapsed or refractory acute myeloid leukemia space REZLIDHIA competes with ivosidenib but differentiates itself through a favorable safety profile and durable responses in heavily pretreated patients. For GAVRETO the primary competitor is selpercatinib however Rigel benefits from orphan drug exclusivity and a once daily oral dosing regimen that may improve adherence. Across all programs Rigel leverages its expertise in kinase inhibition intellectual property protection and strategic collaborations to maintain a defensible position.
Rigel’s customers are principally hematologists oncologists and other healthcare professionals who prescribe its therapies to adult and pediatric patients with specific indications. The company distributes its products through third party wholesale distributors specialty pharmacies and group purchasing organizations before they reach the point of care. In the United States Rigel supports access through its patient assistance program Rigel OneCare which provides copay assistance to commercially insured patients and free product to qualifying uninsured or underinsured individuals. Internationally the company relies on partners such as Kissei in Japan Korea and Taiwan Dr. Reddy’s in Latin America and other regions and Medison in Canada and Israel to commercialize its products. While specific corporate customer names are not disclosed in the filing the base comprises medical institutions clinics and pharmacies that serve the patient populations targeted by Rigel’s therapies.
Sector:HealthcareSector rationaleRigel Pharmaceuticals is a biotechnology company that develops and sells prescription therapies for hematologic disorders and cancer, such as TAVALISSE and REZLIDHIA. Its revenue is derived from the sale of these medical products to healthcare professionals and patients, as well as licensing and royalty agreements within the pharmaceutical industry.Industry:BiotechnologyBiotechnologyPrimaryRigel is described as a biotechnology company that develops therapies derived from biological science, specifically targeting signaling pathways for hematologic disorders and cancer. Its revenue is derived from the sale of biologic-based products like TAVALISSE, REZLIDHIA, and GAVRETO, as well as collaboration and milestone payments.Classified using BQ-MICSCIK: 0001034842
Bull & bear
Investment Thesis
▲ Bull case
Rigel Pharmaceuticals is strategically positioned to transform from a profitable commercial entity into a long-term growth powerhouse through its pipeline asset R289, which has demonstrated compelling early efficacy in heavily pretreated lower-risk MDS patients with 33% achieving ≥8-week RBC-TI at 500 mg dose or higher, a median duration of 23 weeks, and onset around two months, all while maintaining a favorable safety profile with low Grade 3/4 cytopenia and infection rates, suggesting meaningful clinical benefit in an area of high unmet need where current therapies like luspatercept and imetelstat only achieve 40% response rates, indicating R289 could meaningfully improve upon existing standards and capture significant market share in a patient population of approximately 12,000 previously treated lower-risk MDS patients in the U.S. alone.
The company’s recent exclusive global license agreement for VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for ESR1-mutated advanced breast cancer, represents a de-risked, near-term commercial catalyst with FDA approval already secured on May 1, 2026, NCCN Guidelines inclusion as a Category 2A treatment option on May 8, 2026, and compelling Phase 3 VERITAC-2 data showing a 43% reduction in risk of disease progression or death versus fulvestrant and median PFS of 5.0 months versus 2.1 months, positioning VEPPANU to become a meaningful revenue contributor by mid-2026 upon expected deal closure, leveraging Rigel’s proven commercial infrastructure to rapidly integrate and launch the asset with limited incremental cost, consistent with prior successes in integrating GAVRETO and RESLIDIA.
Rigel’s financial discipline and capital allocation strategy are underappreciated by the market, as evidenced by its ability to grow net product sales 60% year-over-year in 2025 to $232 million while simultaneously increasing R&D investment to advance R289 and elutacitinib, maintaining profitability and generating over $100 million in cumulative cash since 2024, with year-end cash, cash equivalents, and short-term investments reaching $155 million—up from $77.3 million—providing a substantial warhead to pursue additional NDA-ready or recently approved hematology/oncology assets that are accretive and cash-generative, supporting management’s stated goal of portfolio expansion by 2028 through disciplined in-licensing and acquisition of late-stage opportunities that leverage existing infrastructure for rapid, sustainable growth.
The company’s international expansion strategy for TAVALISSE via established partnerships with Grifols (Europe), Kissei (Asia), and Medison (Canada, Israel) is creating a scalable, low-cost pathway to global market penetration, with additional regulatory submissions underway and RESLIDIA already under exclusive license with Dr. Reddy’s for its territory, enabling Rigel to monetize its hematology franchise beyond the U.S. without significant sales force expansion, as evidenced by Q1 2026 contract revenue of $3.9 million driven by royalties and supply agreements, demonstrating that global commercialization is already contributing meaningfully to top-line growth and diversifying revenue streams away from U.S.-centric execution risks.
R289 holds FDA Fast Track and Orphan Drug Designation for MDS, granting expedited review, potential priority review, and seven years of exclusivity upon approval, which, combined with the ongoing dose-expansion phase targeting completion and recommended Phase 2 dose selection in the second half of 2026 with top-line data anticipated by year-end, creates a clear, near-term regulatory pathway that could accelerate registration discussions with the FDA post-Phase 1b, reducing development timelines and increasing the probability of successful commercialization in a niche but addressable patient population with limited therapeutic options and high willingness to pay for innovative mechanisms.
Rigel Pharmaceuticals is strategically positioned to transform from a profitable commercial entity into a long-term growth powerhouse through its pipeline asset R289, which has demonstrated compelling early efficacy in heavily pretreated lower-risk MDS patients with 33% achieving ≥8-week RBC-TI at 500 mg dose or higher, a median duration of 23 weeks, and onset around two months, all while maintaining a favorable safety profile with low Grade 3/4 cytopenia and infection rates, suggesting meaningful clinical benefit in an area of high unmet need where current therapies like luspatercept and imetelstat only achieve 40% response rates, indicating R289 could meaningfully improve upon existing standards and capture significant market share in a patient population of approximately 12,000 previously treated lower-risk MDS patients in the U.S. alone.
The company’s recent exclusive global license agreement for VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for ESR1-mutated advanced breast cancer, represents a de-risked, near-term commercial catalyst with FDA approval already secured on May 1, 2026, NCCN Guidelines inclusion as a Category 2A treatment option on May 8, 2026, and compelling Phase 3 VERITAC-2 data showing a 43% reduction in risk of disease progression or death versus fulvestrant and median PFS of 5.0 months versus 2.1 months, positioning VEPPANU to become a meaningful revenue contributor by mid-2026 upon expected deal closure, leveraging Rigel’s proven commercial infrastructure to rapidly integrate and launch the asset with limited incremental cost, consistent with prior successes in integrating GAVRETO and RESLIDIA.
Rigel’s financial discipline and capital allocation strategy are underappreciated by the market, as evidenced by its ability to grow net product sales 60% year-over-year in 2025 to $232 million while simultaneously increasing R&D investment to advance R289 and elutacitinib, maintaining profitability and generating over $100 million in cumulative cash since 2024, with year-end cash, cash equivalents, and short-term investments reaching $155 million—up from $77.3 million—providing a substantial warhead to pursue additional NDA-ready or recently approved hematology/oncology assets that are accretive and cash-generative, supporting management’s stated goal of portfolio expansion by 2028 through disciplined in-licensing and acquisition of late-stage opportunities that leverage existing infrastructure for rapid, sustainable growth.
The company’s international expansion strategy for TAVALISSE via established partnerships with Grifols (Europe), Kissei (Asia), and Medison (Canada, Israel) is creating a scalable, low-cost pathway to global market penetration, with additional regulatory submissions underway and RESLIDIA already under exclusive license with Dr. Reddy’s for its territory, enabling Rigel to monetize its hematology franchise beyond the U.S. without significant sales force expansion, as evidenced by Q1 2026 contract revenue of $3.9 million driven by royalties and supply agreements, demonstrating that global commercialization is already contributing meaningfully to top-line growth and diversifying revenue streams away from U.S.-centric execution risks.
R289 holds FDA Fast Track and Orphan Drug Designation for MDS, granting expedited review, potential priority review, and seven years of exclusivity upon approval, which, combined with the ongoing dose-expansion phase targeting completion and recommended Phase 2 dose selection in the second half of 2026 with top-line data anticipated by year-end, creates a clear, near-term regulatory pathway that could accelerate registration discussions with the FDA post-Phase 1b, reducing development timelines and increasing the probability of successful commercialization in a niche but addressable patient population with limited therapeutic options and high willingness to pay for innovative mechanisms.
Rigel Pharmaceuticals’ 2026 revenue guidance of $275–$290 million, implying only double-digit growth off a 2025 base of $294.3 million in total revenue, appears conservative and may reflect unspoken concerns about the sustainability of its commercial momentum, particularly given management’s explicit acknowledgment that the 60% net product sales growth in 2025 was driven by a nonrecurring “onetime favorable effect from increased affordability” due to the elimination of the Medicare Part D coverage gap, which is not expected to recur, leaving the company to rely solely on organic demand growth in a competitive landscape where TAVALISSE faces established TPO-RAs and GAVRETO contends with other RET inhibitors like selpercatinib in a crowded NSCLC market.
Despite promising Phase 1b data for R289 in heavily pretreated lower-risk MDS, the 33% RBC-TI rate at 500 mg or higher is based on only 18 evaluable patients, a small sample size that limits statistical confidence and generalizability, and the median duration of 23 weeks, while encouraging, falls short of the durable transfusion independence seen with approved agents like luspatercept and imetelstat in less heavily pretreated populations, raising concerns that R289’s efficacy may not translate to earlier-line patients or demonstrate sufficient durability to support a registration trial, especially given the lack of comparative data against standard of care and the absence of a clear path to demonstrating superiority or non-inferiority in a pivotal study.
The company’s reliance on in-licensing and acquisition for portfolio expansion introduces significant execution risk, as Rigel’s strategy hinges on identifying and integrating NDA-ready or recently approved hematology/oncology assets by 2028, yet the biotech M&A market remains highly competitive and valuation-sensitive, with late-stage assets often commanding premiums that may not be accretive given Rigel’s current market capitalization, and there is no guarantee that suitable targets will emerge on favorable terms, particularly as management admitted they are continuously evaluating opportunities but cannot predict when a deal will “fall into place,” creating uncertainty around timing and success of this critical growth lever.
VEPPANU’s potential contribution to Rigel’s growth is contingent on successful integration and commercialization of a PROTAC asset outside Rigel’s core hematology/oncology expertise, with the drug’s label restricted to ESR1-mutated advanced breast cancer after at least one line of endocrine therapy—a niche subset of an already small patient population (approximately 50% of ER+/HER2- patients develop ESR1 mutations, translating to roughly 25,000–30,000 eligible patients in the U.S.)—and while the VERITAC-2 PFS benefit is statistically significant, the median PFS of 5.0 months is modest, and overall survival data remain immature, limiting the perceived clinical differentiation and potentially constraining pricing power and reimbursement support in a cost-sensitive oncology market.
Rigel’s international expansion, while progressing through partnerships, remains dependent on third parties like Grifols, Kissei, and Medison for regulatory approvals and market access, with no ownership or direct control over commercialization timelines or pricing strategies in key regions such as Europe and Asia, exposing the company to partner-dependent delays, divergent commercial priorities, and potential underperformance if partners fail to prioritize Rigel’s products, as evidenced by the prior-year contract revenue decline from $9.8 million in Q1 2025 to $3.9 million in Q1 2026 due to the lapse of a one-time $3.0 million regulatory milestone from Korea, highlighting the volatility and unpredictability of collaboration-driven revenue.
Rigel Pharmaceuticals’ 2026 revenue guidance of $275–$290 million, implying only double-digit growth off a 2025 base of $294.3 million in total revenue, appears conservative and may reflect unspoken concerns about the sustainability of its commercial momentum, particularly given management’s explicit acknowledgment that the 60% net product sales growth in 2025 was driven by a nonrecurring “onetime favorable effect from increased affordability” due to the elimination of the Medicare Part D coverage gap, which is not expected to recur, leaving the company to rely solely on organic demand growth in a competitive landscape where TAVALISSE faces established TPO-RAs and GAVRETO contends with other RET inhibitors like selpercatinib in a crowded NSCLC market.
Despite promising Phase 1b data for R289 in heavily pretreated lower-risk MDS, the 33% RBC-TI rate at 500 mg or higher is based on only 18 evaluable patients, a small sample size that limits statistical confidence and generalizability, and the median duration of 23 weeks, while encouraging, falls short of the durable transfusion independence seen with approved agents like luspatercept and imetelstat in less heavily pretreated populations, raising concerns that R289’s efficacy may not translate to earlier-line patients or demonstrate sufficient durability to support a registration trial, especially given the lack of comparative data against standard of care and the absence of a clear path to demonstrating superiority or non-inferiority in a pivotal study.
The company’s reliance on in-licensing and acquisition for portfolio expansion introduces significant execution risk, as Rigel’s strategy hinges on identifying and integrating NDA-ready or recently approved hematology/oncology assets by 2028, yet the biotech M&A market remains highly competitive and valuation-sensitive, with late-stage assets often commanding premiums that may not be accretive given Rigel’s current market capitalization, and there is no guarantee that suitable targets will emerge on favorable terms, particularly as management admitted they are continuously evaluating opportunities but cannot predict when a deal will “fall into place,” creating uncertainty around timing and success of this critical growth lever.
VEPPANU’s potential contribution to Rigel’s growth is contingent on successful integration and commercialization of a PROTAC asset outside Rigel’s core hematology/oncology expertise, with the drug’s label restricted to ESR1-mutated advanced breast cancer after at least one line of endocrine therapy—a niche subset of an already small patient population (approximately 50% of ER+/HER2- patients develop ESR1 mutations, translating to roughly 25,000–30,000 eligible patients in the U.S.)—and while the VERITAC-2 PFS benefit is statistically significant, the median PFS of 5.0 months is modest, and overall survival data remain immature, limiting the perceived clinical differentiation and potentially constraining pricing power and reimbursement support in a cost-sensitive oncology market.
Rigel’s international expansion, while progressing through partnerships, remains dependent on third parties like Grifols, Kissei, and Medison for regulatory approvals and market access, with no ownership or direct control over commercialization timelines or pricing strategies in key regions such as Europe and Asia, exposing the company to partner-dependent delays, divergent commercial priorities, and potential underperformance if partners fail to prioritize Rigel’s products, as evidenced by the prior-year contract revenue decline from $9.8 million in Q1 2025 to $3.9 million in Q1 2026 due to the lapse of a one-time $3.0 million regulatory milestone from Korea, highlighting the volatility and unpredictability of collaboration-driven revenue.